Dr. Mark Rosenberg received his undergraduate degree from the University of Pennsylvania and his medical degree from Georgetown University School of Medicine in 1988. Dr. Rosenberg completed his residency in emergency medicine where he was awarded “Resident and Teacher of the Year.” Dr. Rosenberg has been director/assistant director of several emergency departments, including Walter Reed Army Medical Center. Approximately 17 years ago, after diagnosing his mother with metastatic lung cancer, Dr. Rosenberg began treating patients with advanced-stage cancer, and became a cancer researcher. Dr. Rosenberg started a pharmaceutical company, which merged with a spin-out of Harvard. A phase I trial will be initiated first quarter 2022, with a new drug that targets cancer stem cells. Dr. Rosenberg recently filed a patent on a device that will decrease the ability of cancer cells to leave circulation, thereby reducing metastatic seeding.